Sangeeta Jiwtani

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Imatinib is the frontline therapy for chronic myeloid leukemia (CML) management. Most of the CML patients achieve major responses, but a proportion (nearly 25–35 %) of them develop drug resistance. Molecular monitoring using quantitative real-time PCR at regular intervals according to European LeukemiaNet (ELN) helps in the assessment of long-term outcomes(More)
  • 1